Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial.
Robert John Motzer
No relevant relationships to disclose
Thomas E. Hutson
No relevant relationships to disclose
Mark R. Olsen
No relevant relationships to disclose
Gary R. Hudes
No relevant relationships to disclose
John M. Burke
No relevant relationships to disclose
William Jeffery Edenfield
No relevant relationships to disclose
George Wilding
No relevant relationships to disclose
Bridget Martell
No relevant relationships to disclose
Subramanian Hariharan
No relevant relationships to disclose
Robert A. Figlin
No relevant relationships to disclose